Comparison Overview

Chiesi USA, Inc.

VS

Intas Pharmaceuticals

Chiesi USA, Inc.

175 Regency Woods Place, Ste 600, Cary, North Carolina, US, 27518
Last Update: 2025-12-22
View Profile
Between 650 and 699
http://chiesiusa.com/

Chiesi USA, Inc., headquartered in Cary, N.C., is a specialty pharmaceutical company focused on commercialization of products for the hospital, rare disease and target office-based specialties. Our employees take an entrepreneurial approach to meet the evolving needs of our customers. As a Public Benefit Corporation, Chiesi USA is committed to operating as a good corporate citizen; positively impacting communities in which we live and serve. Headquartered in Cary NC, we employ over 360 employees in the United States. Previously known as Cornerstone Therapeutics, the company was acquired by the Chiesi Group in 2014. Chiesi USA, Inc. is a wholly-owned subsidiary of Chiesi Farmaceutici S.p.A. Headquartered in Parma, Italy, Chiesi Farmaceutici is an international research-focused group with more than 80 years of experience in the pharmaceutical industry. The Group employs more than 5,300 people in 27 affiliates worldwide, selling products in more than 80 countries. Chiesi is recognized as a top 50 company in terms of revenue and R&D. Careers at Chiesi USA Inc: Email: [email protected] Business Development: Email: [email protected] All other inquiries: Email: [email protected]

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 532
Subsidiaries: 2
12-month incidents
1
Known data breaches
1
Attack type number
1
View Profile

Intas Pharmaceuticals

Sarkhej Gandhinagar Highway, Near Sola Bridge, Ahmedabad, Gujarat, IN
Last Update: 2025-12-19
Between 750 and 799
https://intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 18,700
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/chiesi-usa.jpeg
Chiesi USA, Inc.
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
Chiesi USA, Inc.
100%
Compliance Rate
0/4 Standards Verified
Intas Pharmaceuticals
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

Chiesi USA, Inc. has 8.7% more incidents than the average of same-industry companies with at least one recorded incident.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Intas Pharmaceuticals in 2025.

Incident History — Chiesi USA, Inc. (X = Date, Y = Severity)

Chiesi USA, Inc. cyber incidents detection timeline including parent company and subsidiaries

Incident History — Intas Pharmaceuticals (X = Date, Y = Severity)

Intas Pharmaceuticals cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/chiesi-usa.jpeg
Chiesi USA, Inc.
Incidents

Date Detected: 12/2025
Type:Breach
Blog: Blog
https://images.rankiteo.com/companyimages/intas-pharmaceuticals.jpeg
Intas Pharmaceuticals
Incidents

No Incident

FAQ

Intas Pharmaceuticals company demonstrates a stronger AI Cybersecurity Score compared to Chiesi USA, Inc. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Chiesi USA, Inc. company has historically faced a number of disclosed cyber incidents, whereas Intas Pharmaceuticals company has not reported any.

In the current year, Chiesi USA, Inc. company has reported more cyber incidents than Intas Pharmaceuticals company.

Neither Intas Pharmaceuticals company nor Chiesi USA, Inc. company has reported experiencing a ransomware attack publicly.

Chiesi USA, Inc. company has disclosed at least one data breach, while the other Intas Pharmaceuticals company has not reported such incidents publicly.

Neither Intas Pharmaceuticals company nor Chiesi USA, Inc. company has reported experiencing targeted cyberattacks publicly.

Neither Chiesi USA, Inc. company nor Intas Pharmaceuticals company has reported experiencing or disclosing vulnerabilities publicly.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds any compliance certifications.

Neither company holds any compliance certifications.

Chiesi USA, Inc. company has more subsidiaries worldwide compared to Intas Pharmaceuticals company.

Intas Pharmaceuticals company employs more people globally than Chiesi USA, Inc. company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds SOC 2 Type 1 certification.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds SOC 2 Type 2 certification.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds ISO 27001 certification.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds PCI DSS certification.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds HIPAA certification.

Neither Chiesi USA, Inc. nor Intas Pharmaceuticals holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability has been found in SeaCMS up to 13.3. The affected element is an unknown function of the file js/player/dmplayer/dmku/class/mysqli.class.php. Such manipulation of the argument page/limit leads to sql injection. The attack can be executed remotely. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in HappyDevs TempTool allows Stored XSS.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in Tormorten WP Microdata allows Stored XSS.This issue affects WP Microdata: from n/a through 1.0.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 6.5
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L
References
Description

Exposure of Sensitive System Information to an Unauthorized Control Sphere vulnerability in HappyDevs TempTool allows Retrieve Embedded Sensitive Data.This issue affects TempTool: from n/a through 1.3.1.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:N/A:N
References
Description

A vulnerability has been found in Tenda FH1201 1.2.0.14(408). Affected is the function sprintf of the file /goform/SetIpBind. Such manipulation of the argument page leads to stack-based buffer overflow. The attack may be performed from remote. The exploit has been disclosed to the public and may be used.

Published
Date
2025-12-21
Updated
Date
2025-12-21
Risk Information
cvss2
Base: 9.0
Severity: LOW
AV:N/AC:L/Au:S/C:C/I:C/A:C
cvss3
Base: 8.8
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H
cvss4
Base: 7.4
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References